FDA Rejects Teva Huntington Disease NDA

Teva received a Complete Response Letter from the FDA regarding the NDA for SD-809 (deutetrabenazine) tablets for the treatment of chorea associated Huntington disease (HD).
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news